219 related articles for article (PubMed ID: 8554028)
1. Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long-term results.
Colozza M; Gori S; Mosconi AM; Anastasi P; de Angelis V; Giansanti M; Mercati U; Aristei C; Latini P; Tonato M
Am J Clin Oncol; 1996 Feb; 19(1):10-7. PubMed ID: 8554028
[TBL] [Abstract][Full Text] [Related]
2. The role of surgery in the combined treatment of locally advanced breast cancer.
Canavese G; Catturich A; Battistini G; Caroti C; Pronzato P; Gardin G; Amoroso D; Bertelli G; Conte PF; Tomao S
Oncology; 1989; 46(6):353-6. PubMed ID: 2587002
[TBL] [Abstract][Full Text] [Related]
3. Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy.
Thomas F; Arriagada R; Spielmann M; Mouriesse H; Le Chevalier T; Fontaine F; Tursz T
Cancer; 1995 Dec; 76(11):2286-90. PubMed ID: 8635033
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) or cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in 69 cases of locally advanced (stage IIIb) breast cancer.
Gupta P; Bijlani L; Rath GK; Misra A; Mishra MC; Shukla NK; Kriplani A; Kapur BM
Jpn J Surg; 1991 Nov; 21(6):637-42. PubMed ID: 1787609
[TBL] [Abstract][Full Text] [Related]
5. Ten-year outcome after combined modality therapy for inflammatory breast cancer.
Harris EE; Schultz D; Bertsch H; Fox K; Glick J; Solin LJ
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1200-8. PubMed ID: 12654428
[TBL] [Abstract][Full Text] [Related]
6. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy.
Hortobagyi GN; Ames FC; Buzdar AU; Kau SW; McNeese MD; Paulus D; Hug V; Holmes FA; Romsdahl MM; Fraschini G
Cancer; 1988 Dec; 62(12):2507-16. PubMed ID: 3056604
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099.
Alvarez RH; Booser DJ; Cristofanilli M; Sahin AA; Strom EA; Guerra L; Kau SW; Gonzalez-Angulo AM; Hortobagyi GN; Valero V
Cancer; 2010 Mar; 116(5):1210-7. PubMed ID: 20082452
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer.
Erol K; Baltali E; Altundag K; Guler N; Ozisik Y; Onat DA; Sayek I; Cengiz M; Atahan L; Tekuzman G
Onkologie; 2005 Feb; 28(2):81-5. PubMed ID: 15662111
[TBL] [Abstract][Full Text] [Related]
10. Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy.
Blumenschein GR; DiStefano A; Caderao J; Fristenberg B; Adams J; Schweichler LH; Drinkard L
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2633-7. PubMed ID: 10068266
[TBL] [Abstract][Full Text] [Related]
11. Multimodality treatment of noninflammatory stage IIIb breast cancer.
Gliński B; Pawlicki M; Reinfuss M; Skołyszewski J; Brandys A; Krzemieniecki K; Zuchowska B; Mitus J; Stelmach A; Walasek T
J Surg Oncol; 1997 Nov; 66(3):179-85. PubMed ID: 9369963
[TBL] [Abstract][Full Text] [Related]
12. Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: complete response predicts outcome and allows for breast conservation.
Arthur DW; Schmidt-Ullrich RK; Friedman RB; Wazer DE; Kachnic LA; Amir C; Bear HD; Hackney MH; Smith TJ; Lawrence W
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):289-96. PubMed ID: 10760421
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
14. Role of adjuvant chemotherapy in male breast cancer.
Patel HZ; Buzdar AU; Hortobagyi GN
Cancer; 1989 Oct; 64(8):1583-5. PubMed ID: 2676137
[TBL] [Abstract][Full Text] [Related]
15. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).
Viens P; Palangié T; Janvier M; Fabbro M; Roché H; Delozier T; Labat JP; Linassier C; Audhuy B; Feuilhade F; Costa B; Delva R; Cure H; Rousseau F; Guillot A; Mousseau M; Ferrero JM; Bardou VJ; Jacquemier J; Pouillart P
Br J Cancer; 1999 Oct; 81(3):449-56. PubMed ID: 10507769
[TBL] [Abstract][Full Text] [Related]
16. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer.
Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Sniecinski I
Cancer; 1994 Jan; 73(1):125-34. PubMed ID: 7903906
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
18. The management of locally advanced breast cancer: a combined modality approach.
Kantarjian HM; Hortobagyi GN; Smith TL; Blumenschein GR; Montague E; Buzdar AU; Martin RG
Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1353-61. PubMed ID: 6548710
[TBL] [Abstract][Full Text] [Related]
19. Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer.
Touboul E; Buffat L; Lefranc JP; Blondon J; Deniaud E; Mammar H; Laugier A; Schlienger M
Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1019-28. PubMed ID: 8600084
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients.
Ezzat AA; Ibrahim EM; Ajarim DS; Rahal MM; Raja MA; Tulbah AM; Al-Malik OA; Al-Shabanah M; Sorbris R
Br J Cancer; 2004 Mar; 90(5):968-74. PubMed ID: 14997191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
